Table 5.

Treatment and survival summary 10 patients with Primary CNS Post-Transplant Lymphoproliferative Disorder.

Patient	Age	Time to PTLD diagnosis† (years)	Histological Subtype	Treatments	Overall survival (years)‡	Survival status‡	Organ failure‡
1	42	3.1	Polymorphic	ROI, DEX HD-MTX (1 cycle) WBRT	6.3	Died (non-PTLD)	No
2	67	11.4	Monomorphic, Diffuse large B cell	ROI, DEX Rituximab WBRT	4.9	Died (non-PTLD)	No
3	44	5.8	Monomorphic, Peripheral T Cell	ROI, DEX Rituximab WBRT	0.6	Died (non-PTLD)	Yes
4	47	2.7	Monomorphic, Diffuse large B cell	ROI, DEX Rituximab WBRT	4.3	Alive	Yes
5	38	1.8	Polymorphic	ROI, DEX HD-MTX (3 cycles) Rituximab IT-MTX WBRT Temozolomide	3.3	Alive	No
6	55	1.9	Monomorphic, Diffuse large B cell	ROI, DEXHD-MTX (1 cycle) Rituximab IT-MTX WBRT Temozolomide	2.1	Alive	No
7	56	6.3	Polymorphic	ROI, DEX Rituximab	1.4	Alive	Yes
8	43	9.7	Monomorphic, Diffuse large B cell	ROI, DEX Rituximab	0.2	Died (PTLD)	No
9	63	1.9	Monomorphic, Diffuse large B cell	ROI, DEX WBRT Rituximab	0.8	Alive	No
10	50	11.3	Polymorphic	ROI, DEX	0.3	Alive	No

Abbreviations: DEX = dexamethasone, HD-MTX = high-dose methotrexate 3.5 grams/m² IV per cycle, IT-MTX = intrathecal methotrexate, ROI = reduction of immunosuppresion, WBRT = whole-brain radiotherapy.

^†Time from date of most recent SOT to date of PCNS-PTLD diagnosis.

^‡Outcomes measured from date of PCNS-PTLD diagnosis.